Araştırma Makalesi
BibTex RIS Kaynak Göster

Dyslipidemia Pattern in Rheumatoid Arthritis Patients with Correlation of Disease Activity

Yıl 2017, Cilt: 7 Sayı: 2, 132 - 137, 29.05.2017
https://doi.org/10.16899/gopctd.316827

Öz

Aim: Rheumatoid arthritis (RA) is a multi-factorial disease which affects the immune system and ultimately various tissues in the body that typically affects middle-aged individuals. Our objectives were to evaluate prevalence of dyslipidemias and its pattern in RA patients in Central India and correlate dyslipidemia with disease activity.

Material and methods: This cross-sectional study was conducted on RA patients at Sri Aurobindo Institute of Medical Sciences and Post Graduate Institute, Indore (M.P.) between January 2014 and December 2015. Lipid profiles were determined following 12-hour overnight fasting, and the association of lipid profiles with and disease activity was determined. Results: The maximum number of cases presented in the age group was 41-50(36%). Disease is more prevalent in female population. Maximum number of pateints (34 patients) had duration of illness ranged between 1 to 10 years. Most of the patients presented with high disease activity (90%). Total cholesterol levels were significantly higher in female cases as compared to controls. Similar to total cholesterol, Low density lipoprotein (LDL) cholesterol was significantly higher in female cases as compared to controls. There was no significant difference of High density lipoprotein(HDL), Very low density lipoprotein(VLDL) and Triglyceride(TG) between cases and controls. Mean lipid profile values were similar in male cases and controls. Positive correlation of Disease activity score (DAS)-28 Erythrocyte sedimentation rate (ESR) was observed with total cholesterol and LDL levels in female patients only. No correlation of HDL, LDL and triglyceride were observed with DAS- 28 and ESR in both male and female patients. Conclusions: Lipid profiles were similar in both treatment naive and on treatment patients. No significant difference in mean lipid profile values expect HDL was observed in two groups created on the basis of RA factor. A lipid profile value has no positive or negative correlation with duration of illness. aim: Rheumatoid arthritis (RA) is a multi-factorial disease which affects the immune system and ultimately various tissues in the body that typically affects middle-aged individuals. Our objectives were to evaluate prevalence of dyslipidemias and its pattern in RA patients in Central India and correlate dyslipidemia with disease activity.Material and methods: This cross-sectional study was conducted on RA patients at Sri Aurobindo Institute of Medical Sciences and Post Graduate Institute, Indore (M.P.) between January 2014 and December 2015. Lipid profiles were determined following 12-hour overnight fasting, and the association of lipid profiles with and disease activity was determined.

Results: The maximum number of cases presented in the age group was 41-50(36%). Disease is more prevalent in female population. Maximum number of pateints (34 patients) had duration of illness ranged between 1 to 10 years. Most of the patients presented with high disease activity (90%). Total cholesterol levels were significantly higher in female cases as compared to controls. Similar to total cholesterol, Low density lipoprotein (LDL) cholesterol was significantly higher in female cases as compared to controls. There was no significant difference of High density lipoprotein(HDL), Very low density lipoprotein(VLDL) and Triglyceride(TG) between cases and controls. Mean lipid profile values were similar in male cases and controls. Positive correlation of Disease activity score (DAS)-28 Erythrocyte sedimentation rate (ESR) was observed with total cholesterol and LDL levels in female patients only. No correlation of HDL, LDL and triglyceride were observed with DAS- 28 and ESR in both male and female patients.

Conclusions: Lipid profiles were similar in both treatment naive and on treatment patients. No significant difference in mean lipid profile values expect HDL was observed in two groups created on the basis of RA factor. A lipid profile value has no positive or negative correlation with duration of illness.







Kaynakça

  • 1. Klareskog L, Catrina, AI, Paget S. Rheumatoid arthritis. Lancet 2009, 373(9664): 659-672. 2. Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol 2009; 4:417-34. 3. Cronstein BC, Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum 1993; 36:147-157. 4. Jalkanen S. Leukocyte-endothelial cell interaction and the control of leukocyte migration into inflamed synovium. Springer Semin Immunopathol 1989; 11:187-198. 5. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011; 31: 399-408. 6. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005; 52:3045-53. 7. Yiu KH, Tse HF, Mok MY, Lau CS. Ethnic differences in cardiovascular risk in rheumatic disease: focus on Asians. Nat Rev Rheumatol. 2011; 7: 609-18. 8. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “highgrade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003; 108:2957-63. 9. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors including thrombotic variables in a population with rheumatoid arthritis. Rheumatol. 2001; 40:640-4. 10. MA Gonzalez, CJ Gonzalez, Pineiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005; 32:1219-23. 11. Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2009; 61:1580-5. 12. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther. 2006; 8:82. 13. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003; 62:842-845. 14. Chung CP, Giles JT, Petri M, Szklo M, Post W, Blumenthal RS et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum. 2012; 41:535-544. 15. Dursunoglu D, Evrengul H, Polat B, Tanriverdi H, Cobankara V, Kaftan A et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-245. 16. Rizzo M, Spinas GA, Cesur M, Ozbalkan Z, Rini GB, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis 2009; 207(2):5026. 17. Ghosh UC, Roy A, Sen K, Kundu AK, Saha I, Biswas A. Dyslipidaemia in rheumatoid arthritis in a tertiary care centre in Eastern India--a non-randomised trial. J Indian Med Assoc. 2009; 107(7):427-30 18. Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis. 2009; 68(4):54651 19. Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid-associated cardiovascular risk. Ann Rheum Dis. 2010;69(4):6838. 20. Deswal S, Deswal M, Goel V, Singh H. Dyslipidemia in Rheumatoid Arthritis. Int J Health Sci Res. 2016; 6(1):180-184. 21. Mullick OS, Bhattacharya R, Bhattacharyya K, Sarkar RN, Das A, Chakraborty D, et al. Lipid profile and its relationship with endothelial dysfunction and disease activity in patients of early Rheumatoid Arthritis. Indian J Rheumatol. 2014;9(1):9- 13. 22. Curtis JR, John A, and Baser O. Dyslipidemia and Changes in Lipid Profiles Associated with Rheumatoid Arthritis and Initiation of Anti-TNF Therapy. Arthritis Care Res (Hoboken) 2012;64(9):1282–129 23. Lakator J, Harray S. Serum total, HDL, LDL Cholesterol and Triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988; 21:93-5. 24. Hafstrom I, Rohani M, Deneberg S, Wornert M, Jogestrand T, Frostegard J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. J Rheumatol 2007; 34:1810-6. 25. Svenson KL, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987; 147:1917-20.

Romatoid Artritli Hastalarda Dislipidemi Paterni ve Hastalık Aktivitesi ile İlişkisi

Yıl 2017, Cilt: 7 Sayı: 2, 132 - 137, 29.05.2017
https://doi.org/10.16899/gopctd.316827

Öz



Amaç: Romatoid artrit (RA), bağışıklık sistemini ve nihayetinde orta yaşlı bireyleri etkileyen vücudun çeşitli dokularını etkileyen çok faktörlü bir hastalıktır. Orta Hindistan'daki RA hastalarında dislipidemi prevalansını ve paternini değerlendirmek ve dislipidemi ile hastalık aktivitesini ilişkilendirmek amaçlandı.

Materyal ve Metod: Kesitsel tipteki bu çalışma, Ocak 2014 ile Aralık 2015 tarihleri arasında, Indore'da (MP) Sri Aurobindo Tıp Bilimleri Enstitüsü ve Yüksek Lisans Enstitüsü'nde RA hastalarında gerçekleştirildi. Lipid profilleri 12 saatlik bir açlık sonrası belirlendi ve lipit profilleri ile hastalık aktivitesi ilişkisi saptanmıştır.

Bulgular: Yaş gruplarında sunulan olguların maksimum sayısı 41-50 (% 36) idi. Hastalık kadın nüfusta daha yaygındır. Maksimum hasta sayısı (34 hasta) hastalık süresi 1 ila 10 yıl arasında değişiyordu. Hastaların çoğunda hastalık aktivitesi yüksekti (% 90). Toplam kolesterol düzeyi, kadın olgularda kontrol grubuna göre anlamlı derecede yüksekti. Toplam kolestrol benzer şekilde düşük yoğunluklu lipoprotein (LDL) kolestrol kadınlarda kontrollerden daha yüksekti. Olgular ve kontroller arasında Yüksek dansiteli lipoprotein (HDL), Çok düşük dansiteli lipoprotein (VLDL) ve Trigliserid (TG) arasında anlamlı fark yoktu. Erkek olgularda ve kontrollerde ortalama lipid profili değerleri benzerdi. Hastalık aktivite skorunun (DAS)-28 ve eritrosit sedimentasyon hızı (ESR) yalnızca kadın hastalarda total kolesterol ve LDL düzeyleri ile pozitif korelasyonu gözlendi. DAS-28 ve ESR hem kadın hem de erkek hastalarda HDL, LDL ve trigliserid arasında bir korelasyon gözlenmedi.




Sonuç: Lipid profilleri hem naif hem de tedavi edilen hastalarda benzerdi. Ortalama lipid profili değerlerinde anlamlı fark yok RAF faktörüne dayalı olarak oluşturulan iki grupta HDL'nin beklendiği beklendi. Bir lipid profili değeri hastalığın süresi ile pozitif veya negatif korelasyon göstermez.


Kaynakça

  • 1. Klareskog L, Catrina, AI, Paget S. Rheumatoid arthritis. Lancet 2009, 373(9664): 659-672. 2. Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol 2009; 4:417-34. 3. Cronstein BC, Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum 1993; 36:147-157. 4. Jalkanen S. Leukocyte-endothelial cell interaction and the control of leukocyte migration into inflamed synovium. Springer Semin Immunopathol 1989; 11:187-198. 5. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011; 31: 399-408. 6. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005; 52:3045-53. 7. Yiu KH, Tse HF, Mok MY, Lau CS. Ethnic differences in cardiovascular risk in rheumatic disease: focus on Asians. Nat Rev Rheumatol. 2011; 7: 609-18. 8. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “highgrade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003; 108:2957-63. 9. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors including thrombotic variables in a population with rheumatoid arthritis. Rheumatol. 2001; 40:640-4. 10. MA Gonzalez, CJ Gonzalez, Pineiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005; 32:1219-23. 11. Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2009; 61:1580-5. 12. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther. 2006; 8:82. 13. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003; 62:842-845. 14. Chung CP, Giles JT, Petri M, Szklo M, Post W, Blumenthal RS et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum. 2012; 41:535-544. 15. Dursunoglu D, Evrengul H, Polat B, Tanriverdi H, Cobankara V, Kaftan A et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-245. 16. Rizzo M, Spinas GA, Cesur M, Ozbalkan Z, Rini GB, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis 2009; 207(2):5026. 17. Ghosh UC, Roy A, Sen K, Kundu AK, Saha I, Biswas A. Dyslipidaemia in rheumatoid arthritis in a tertiary care centre in Eastern India--a non-randomised trial. J Indian Med Assoc. 2009; 107(7):427-30 18. Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis. 2009; 68(4):54651 19. Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid-associated cardiovascular risk. Ann Rheum Dis. 2010;69(4):6838. 20. Deswal S, Deswal M, Goel V, Singh H. Dyslipidemia in Rheumatoid Arthritis. Int J Health Sci Res. 2016; 6(1):180-184. 21. Mullick OS, Bhattacharya R, Bhattacharyya K, Sarkar RN, Das A, Chakraborty D, et al. Lipid profile and its relationship with endothelial dysfunction and disease activity in patients of early Rheumatoid Arthritis. Indian J Rheumatol. 2014;9(1):9- 13. 22. Curtis JR, John A, and Baser O. Dyslipidemia and Changes in Lipid Profiles Associated with Rheumatoid Arthritis and Initiation of Anti-TNF Therapy. Arthritis Care Res (Hoboken) 2012;64(9):1282–129 23. Lakator J, Harray S. Serum total, HDL, LDL Cholesterol and Triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988; 21:93-5. 24. Hafstrom I, Rohani M, Deneberg S, Wornert M, Jogestrand T, Frostegard J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. J Rheumatol 2007; 34:1810-6. 25. Svenson KL, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987; 147:1917-20.
Toplam 1 adet kaynakça vardır.

Ayrıntılar

Konular Sağlık Kurumları Yönetimi
Bölüm Orjinal Çalışma
Yazarlar

Prakash Joshi Bu kişi benim

Prakhar Kabra Bu kişi benim

Rajesh Kumar Jha Bu kişi benim

Yayımlanma Tarihi 29 Mayıs 2017
Kabul Tarihi 22 Şubat 2017
Yayımlandığı Sayı Yıl 2017 Cilt: 7 Sayı: 2

Kaynak Göster

APA Joshi, P., Kabra, P., & Kumar Jha, R. (2017). Romatoid Artritli Hastalarda Dislipidemi Paterni ve Hastalık Aktivitesi ile İlişkisi. Çağdaş Tıp Dergisi, 7(2), 132-137. https://doi.org/10.16899/gopctd.316827
AMA Joshi P, Kabra P, Kumar Jha R. Romatoid Artritli Hastalarda Dislipidemi Paterni ve Hastalık Aktivitesi ile İlişkisi. J Contemp Med. Haziran 2017;7(2):132-137. doi:10.16899/gopctd.316827
Chicago Joshi, Prakash, Prakhar Kabra, ve Rajesh Kumar Jha. “Romatoid Artritli Hastalarda Dislipidemi Paterni Ve Hastalık Aktivitesi Ile İlişkisi”. Çağdaş Tıp Dergisi 7, sy. 2 (Haziran 2017): 132-37. https://doi.org/10.16899/gopctd.316827.
EndNote Joshi P, Kabra P, Kumar Jha R (01 Haziran 2017) Romatoid Artritli Hastalarda Dislipidemi Paterni ve Hastalık Aktivitesi ile İlişkisi. Çağdaş Tıp Dergisi 7 2 132–137.
IEEE P. Joshi, P. Kabra, ve R. Kumar Jha, “Romatoid Artritli Hastalarda Dislipidemi Paterni ve Hastalık Aktivitesi ile İlişkisi”, J Contemp Med, c. 7, sy. 2, ss. 132–137, 2017, doi: 10.16899/gopctd.316827.
ISNAD Joshi, Prakash vd. “Romatoid Artritli Hastalarda Dislipidemi Paterni Ve Hastalık Aktivitesi Ile İlişkisi”. Çağdaş Tıp Dergisi 7/2 (Haziran 2017), 132-137. https://doi.org/10.16899/gopctd.316827.
JAMA Joshi P, Kabra P, Kumar Jha R. Romatoid Artritli Hastalarda Dislipidemi Paterni ve Hastalık Aktivitesi ile İlişkisi. J Contemp Med. 2017;7:132–137.
MLA Joshi, Prakash vd. “Romatoid Artritli Hastalarda Dislipidemi Paterni Ve Hastalık Aktivitesi Ile İlişkisi”. Çağdaş Tıp Dergisi, c. 7, sy. 2, 2017, ss. 132-7, doi:10.16899/gopctd.316827.
Vancouver Joshi P, Kabra P, Kumar Jha R. Romatoid Artritli Hastalarda Dislipidemi Paterni ve Hastalık Aktivitesi ile İlişkisi. J Contemp Med. 2017;7(2):132-7.